Foundations And Implications For International Reference Pricing

International reference pricing affects every market entry decision you make. With more than 75 countries benchmarking drug costs against one another, a pricing move in one market can trigger unintended consequences across your entire global portfolio. That pressure is intensifying: the U.S. Most Favored Nation model and a wave of IRP reforms are forcing pharmaceutical companies to rethink long-standing assumptions about launch sequencing, value retention, and market sustainability.

This webinar cuts through the complexity to give you a practical foundation for understanding how IRP works, where it is heading, and what it means for your pricing strategy. You will hear real-world examples of IRP-driven pricing pressures and explore how other companies are responding, including tactics for differential pricing and protecting commercial value without sacrificing patient access. Experts from Cencora also address one of the defining tensions in today's environment: how to operate effectively in a market where transparency requirements and confidential pricing agreements must coexist.

This session offers insights to help you build the strategic clarity your pricing team needs before the next policy shift changes the equation.